1. Home
  2. MSDL vs NMRA Comparison

MSDL vs NMRA Comparison

Compare MSDL & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MSDL
  • NMRA
  • Stock Information
  • Founded
  • MSDL 2019
  • NMRA 2019
  • Country
  • MSDL United States
  • NMRA United States
  • Employees
  • MSDL N/A
  • NMRA N/A
  • Industry
  • MSDL
  • NMRA
  • Sector
  • MSDL
  • NMRA
  • Exchange
  • MSDL NYSE
  • NMRA Nasdaq
  • Market Cap
  • MSDL 1.9B
  • NMRA 1.7B
  • IPO Year
  • MSDL N/A
  • NMRA 2023
  • Fundamental
  • Price
  • MSDL $21.61
  • NMRA $2.06
  • Analyst Decision
  • MSDL Buy
  • NMRA Strong Buy
  • Analyst Count
  • MSDL 7
  • NMRA 6
  • Target Price
  • MSDL $21.67
  • NMRA $20.67
  • AVG Volume (30 Days)
  • MSDL 354.2K
  • NMRA 6.2M
  • Earning Date
  • MSDL 01-01-0001
  • NMRA 03-06-2025
  • Dividend Yield
  • MSDL 9.25%
  • NMRA N/A
  • EPS Growth
  • MSDL N/A
  • NMRA N/A
  • EPS
  • MSDL N/A
  • NMRA N/A
  • Revenue
  • MSDL N/A
  • NMRA N/A
  • Revenue This Year
  • MSDL $1,597.39
  • NMRA N/A
  • Revenue Next Year
  • MSDL $15.28
  • NMRA N/A
  • P/E Ratio
  • MSDL N/A
  • NMRA N/A
  • Revenue Growth
  • MSDL N/A
  • NMRA N/A
  • 52 Week Low
  • MSDL $19.05
  • NMRA $1.83
  • 52 Week High
  • MSDL $24.18
  • NMRA $21.00
  • Technical
  • Relative Strength Index (RSI)
  • MSDL 62.87
  • NMRA 20.38
  • Support Level
  • MSDL $20.23
  • NMRA $2.00
  • Resistance Level
  • MSDL $21.17
  • NMRA $2.44
  • Average True Range (ATR)
  • MSDL 0.35
  • NMRA 0.35
  • MACD
  • MSDL 0.07
  • NMRA -0.21
  • Stochastic Oscillator
  • MSDL 94.85
  • NMRA 2.38

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and, to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: